GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.
GLP-1 receptor agonists are highly effective for weight loss and increasing in popularity for those trying to lose weight. One concern with these medications is the potential for loss of lean tissue mass during rapid weight loss. This may affect strength and functional performance in people taking these medications. Resistance-training helps to offset loss of muscle mass during weight loss. Supplementation with creatine monohydrate is also effective for improving muscle mass and strength. The purpose of this pilot study is to determine the effectiveness of creatine supplementation during a resistance training program in people who are starting GLP-receptor agonist medication for preventing loss of lean tissue mass and functional performance. The investigators will randomize 40 people who are starting GLP-1 agonists to receive either 10g per day creatine or placebo during a resistance-training program (i.e., resistance-training three days per week for 12 weeks). It is hypothesized that participants on the creatine supplement will have superior maintenance of lean tissue mass and function performance compared to participants taking placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
40
creatine supplementation
Placebo
University of Saskatchewan
Saskatoon, SK - Saskatchewan, Canada
RECRUITINGChange in sit to stand performance (number of times)
change in number of times sitting and standing in 30 seconds
Time frame: 12 weeks
Change in 10 meter gait speed (m/s)
change in walking speed over 10 meters
Time frame: 12 weeks
Change in timed up and go (m/s)
change in time to stand up, walk 3m, turn, around, walk 3 m and sit down
Time frame: 12 weeks
Change in lean tissue mass (kg)
Change in lean tissue mass as determined by dual energy x-ray absorptiometry
Time frame: 12 weeks
Change in fat mass (kg)
Change in fat mass as determined by dual energy x-ray absorptiometry
Time frame: 12 weeks
Change in whole body bone mineral density (g/cm squared)
Change in bone mineral density as determined by dual energy x-ray absorptiometry
Time frame: 12 weeks
Change in femoral neck bone mineral density (g/cm squared)
Change in bone mineral density as determined by dual energy x-ray absorptiometry
Time frame: 12 weeks
Change in total hip bone mineral density (g/cm squared)
Change in bone mineral density as determined by dual energy x-ray absorptiometry
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in lumbar spine bone mineral density (g/cm squared)
Change in bone mineral density as determined by dual energy x-ray absorptiometry
Time frame: 12 weeks
Change in hip section modulus (cm-cubed)
Change in hip section modulus as determined by dual energy x-ray absorptiometry
Time frame: 12 weeks
Change in muscle thickness of the biceps (cm)
Change in muscle thickness measured by ultrasound
Time frame: 12 weeks
Change in muscle thickness of the quadriceps (cm)
Change in muscle thickness measured by ultrasound
Time frame: 12 weeks
Change in bench press strength (kg)
change in upper body strength measured by predicted one repetition maximum
Time frame: 12 weeks
Change in leg extension strength (kg)
Change in lower body strength measured by predicted one repetition maximum
Time frame: 12 weeks
Change in hip buckling ratio (ratio)
Change in hip buckling ratio as determined by dual energy x-ray absorptiometry
Time frame: 12 weeks
Change in hip cross-sectional area (cm-squared)
Change in hip cross-sectional area as determined by dual energy x-ray absorptiometry
Time frame: 12 weeks
Change in hip cortical thickness (cm)
Change in hip cortical thickness as determined by dual energy x-ray absorptiometry
Time frame: 12 weeks